Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran



Etemadifar M1 ; Mazdeh M2 ; Torabi HR3 ; Ghaffarpour M4 ; Azimian M4 ; Shahkarami SMA5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, Hamedan University of Medical Sciences, Hamedan, Iran
  3. 3. Jam Hospital, Tehran, Iran
  4. 4. Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Isfahan University of Medical Sciences, Isfahan, Iran

Source: Tehran University Medical Journal Published:2010

Abstract

Background: Recent studies present a high prevalence of multiple sclerosis (MS) in Iran. Treatment with interferon is now the first choice in management of MS. CinnoVex™ (an interferon beta 1-a) is available in Iran, with achievement of the technology of producing beta interferon. The aim of the present study is to evaluate the efficacy and safety of CinnoVex™ in a national study named CINA study. Methods: This study was conducted from 2007 to 2008 in cities of Tehran, Isfahan, Mashhad, Tabriz, and Shiraz. Patients with relapsing/remitting MS with 16-50 years of age and EDSS of <4 received CinnoVex™ (30μg/week, IM) after diagnosis by a neurologist. EDSS, drug side effects, and frequency of relapse were evaluated for one year in four 3-month visits. Results: A total of 1050 patients entered the study. Complete data were collected from 627 (60%) patients. Mean age was 30.7±8.6 year and 514 (82%) were female. The most common onset presentations were sensory symptoms (44%). Changes of EDSS through the study showed a significant decrease in the last 3-month of evaluation (p<0.05). Drug side effects were observed in 47%, 50%, 61%, and 61.4% (p>0.05) and relapse was occurred in 13.4%, 15.7%, 16.9%, and 2.4% of the patients in the first, second, third, and forth evaluation visits (p=0.001), respectively. Conclusion: CinnoVex™ prevents progression and improves clinical course of MS. The conventional side effects of beta interferon therapy, however, are observed with CinnoVex™.
Related Docs
View other Related Docs
1. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
2. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
3. Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2011)
4. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
5. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
6. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
7. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
8. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran, European Neurology (2014)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (133)
Masoud Etemadifar (107)
Other Related Docs
9. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
10. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
11. Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review, CNS Neuroscience and Therapeutics (2025)
12. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
13. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
14. Lateonset Multiple Sclerosis in Isfahan, Iran, Archives of Iranian Medicine (2012)
15. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
16. Ongoing Increase in Incidence and Prevalence of Multiple Sclerosis in South-Eastern Iran: A Three Decade Study, Multiple Sclerosis and Related Disorders (2023)
17. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
18. Epidemiology of Familial Multiple Sclerosis in Iran: A National Registry-Based Study, BMC Neurology (2022)
19. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
20. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
21. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
22. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
23. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
24. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
25. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
26. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
27. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
28. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
29. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
30. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
31. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
32. Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis, Canadian Journal of Neurological Sciences (2008)
33. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
34. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
35. Combination Therapy With Mitoxantrone and Plasma Exchange in Aggressive Relapsing Remitting Multiple Sclerosis: A Preliminary Clinical Study, Journal of Research in Medical Sciences (2012)
36. Efficacy of Adding Vitamin D Supplementation to Interferon Β-1 in Multiple Sclerosis, Journal of Isfahan Medical School (2016)
37. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
38. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
39. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
40. Mitoxantrone Reduced Disability in Iranian Patients With Multiple Sclerosis, Archives of Iranian Medicine (2007)
41. Does Early-Onset Multiple Sclerosis Differ From Adult-Onset Form in Iranian People, Journal of Research in Medical Sciences (2010)
42. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
43. Stress Differentially Predicts Multiple Sclerosis Relapses, Neurology Asia (2014)
44. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
45. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
46. Using Discrete Choice Experiment to Determine Willingness to Pay for Interferon-Beta Drugs by Multiple Sclerosis Patients, Iranian Journal of Pharmaceutical Sciences (2018)
47. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
48. Side Effects of Methylprednisolone Pulse Therapy in Treatment of Multiple Sclerosis, Journal of Isfahan Medical School (2012)
49. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
50. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)